Nutcracker Therapeutics
PrivateLast Round
Series C
Mar 14, 2022
Total Funding Raised
$241M
Company Overview
Nutcracker Therapeutics operates in Healthcare & Life Sciences and is based in Emeryville, California. Its latest recorded funding round was a Series C round in March 2022.
Nutcracker Therapeutics is a biotechnology company that develops mRNA-based therapeutic drug products through its innovative platform that integrates proprietary hardware, software, and advancements in mRNA biochemistry and nanoparticle delivery.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Biotech Equipment, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Usage-Based SaaS
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nutcracker Therapeutics Comparables
Compare Nutcracker Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| eTheRNA | 81% | |
| Univercells | 81% | |
| Dillico | 71% |
For institutional investors. Book with your work email.
Nutcracker Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Mar 14, 2022 | ||||
| Series B | Sep 23, 2020 | ||||
| Series A | Mar 21, 2019 | ||||
| Seed | May 17, 2018 |
For institutional investors. Book with your work email.
Nutcracker Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Altitude Life Science Ventures | Series C, Series A |
| ARCH Venture Partners | Series A, Series B, Series C |
| Bluebird Ventures | Series B, Series C, Series A |
| Sutter Hill Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 26, 2025
Cynthia Collins appointed Executive Chair and Interim CEO.
- Sep 23, 2020
$60M round led by ARCH Venture Partners.
For institutional investors. Book with your work email.
Nutcracker Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Nutcracker Therapeutics's valuation, stock price, and market status.
Is Nutcracker Therapeutics a public or private company?
Nutcracker Therapeutics is a private company.
What is the current stock price of Nutcracker Therapeutics?
Nutcracker Therapeutics is a private company, so its shares have no public market price. Caplight tracks Nutcracker Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Nutcracker Therapeutics worth (valuation)?
Valuation information for Nutcracker Therapeutics is not publicly available.
Can I buy Nutcracker Therapeutics stock?
Nutcracker Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Nutcracker Therapeutics's last funding round?
Nutcracker Therapeutics's most recent funding round was Series C on March 14, 2022.
Who are the main investors in Nutcracker Therapeutics?
Key investors in Nutcracker Therapeutics include ARCH Venture Partners.
Will Nutcracker Therapeutics IPO soon?
No public IPO plans have been announced for Nutcracker Therapeutics.
How can I track Nutcracker Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Nutcracker Therapeutics's shares on secondary markets.